Dmitry A. Buletov
Research Subjects
Dmitry A. Buletov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Oleg A. Merkulov
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
4 shared publications - Vladimir G. Polyakov
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
4 shared publications - Tatiana V. Gorbunova
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
3 shared publications - A. V. Sotnikov
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication - Anastasia A. Ushina1 shared publication
- Anton Tikhonov
LLC “NPO Petrovax Farm
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (4) , 41-51
Camrelizumab exhibits dual specificity implications for antitumor immunity
Introduction. Camrelizumab is a high-affinity monoclonal antibody targeting programmed cell death protein 1 (PD-1) that has demonstrated strong clinical activity across multiple solid tumors. Emerging evidence suggests that camrelizumab can bind not only PD-1 but also the stress-induced ligand ULBP2 which activates natural killer (NK) and CD8+-T cells. Aim. To experimentally verify specific camrelizumab binding to ULBP2 (in contrast to reference anti-PD-1 antibodies pembrolizumab, nivolumab, and prolgolimab), compare anti-PD-1 antibodies binding profiles, and explore the potential immunological implications of camrelizumab dual specificity to PD-1 and ULBP2 in the context of antitumor immune response. Materials and methods. Binding interactions between ULBP2 and the four anti-PD-1 antibodies (camrelizumab, pembrolizumab, nivolumab, and prolgolimab) were assessed using surface plasmon resonance and flow cytometry. Results. Among all the tested antibodies, only camrelizumab exhibited specific binding to ULBP2 (KD (equilibrium dissociation constant) = 2.79 × 10–7 M). This interaction was confirmed by two independent methods. Conclusion. Camrelizumab displays a unique dual specificity for PD-1 and ULBP2 maintaining activity of effector lymphocytes and potentially decreases the dependence of therapy efficacy of PD-1 ligand (PD-L1) expression level. These findings expand our understanding of the biological features of camrelizumab and support its potential as an immunomodulator with broadened activity.
- 18 March 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (4) , 41-51
Open AccessCamrelizumab exhibits dual specificity implications for antitumor immunity
Introduction. Camrelizumab is a high-affinity monoclonal antibody targeting programmed cell death protein 1 (PD-1) that has demonstrated strong clinical activity across multiple solid tumors. Emerging evidence suggests that camrelizumab can bind not only PD-1 but also the stress-induced ligand ULBP2 which activates natural killer (NK) and CD8+-T cells. Aim. To experimentally verify specific camrelizumab binding to ULBP2 (in contrast to reference anti-PD-1 antibodies pembrolizumab, nivolumab, and prolgolimab), compare anti-PD-1 antibodies binding profiles, and explore the potential immunological implications of camrelizumab dual specificity to PD-1 and ULBP2 in the context of antitumor immune response. Materials and methods. Binding interactions between ULBP2 and the four anti-PD-1 antibodies (camrelizumab, pembrolizumab, nivolumab, and prolgolimab) were assessed using surface plasmon resonance and flow cytometry. Results. Among all the tested antibodies, only camrelizumab exhibited specific binding to ULBP2 (KD (equilibrium dissociation constant) = 2.79 × 10–7 M). This interaction was confirmed by two independent methods. Conclusion. Camrelizumab displays a unique dual specificity for PD-1 and ULBP2 maintaining activity of effector lymphocytes and potentially decreases the dependence of therapy efficacy of PD-1 ligand (PD-L1) expression level. These findings expand our understanding of the biological features of camrelizumab and support its potential as an immunomodulator with broadened activity.
- Open Access
- 1 December 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (4) , 57-64
EXPERIMENTAL IMMUNOTHERAPY MODEL OF RETINOBLASTOMA
Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.
- 1 December 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (4) , 57-64
Open AccessEXPERIMENTAL IMMUNOTHERAPY MODEL OF RETINOBLASTOMA
Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.
- Open Access
- 19 July 2018
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 5 (2) , 120-126
Sinonasal Hemangiopericytoma in a 12-year-old Boy: Rare Clinical Case
Background.Hemangiopericytoma is a rare type of tumor of vascular origin and unknown malignant potential.Case Report.The article presents clinical case which is rarely observed, especially in children. A 12-year-old boy was admitted to Research Institute of Pediatric Oncology and Hematology with results of head MRI performed at a local clinic which demonstrated presence of a tumor of parameningeal localization. A patient passed complete clinical examination including some radiation diagnostic techniques, MRI, morphological, and immunohistochemical analyses and was diagnosed with sinonasal hemangiopericytoma of parameningeal localization T1bN0M0. The examination schedule, tactics, and treatment methods were selected individually for this patient since a commonly acknowledged treatment method had not been developed due to the lack of statistically relevant number of patient cases. Basing on the data on disease treatment records in Europe and Russia, patient received a complex treatment: three courses of neoadjuvant polychemotherapy, transnasal resection of tumor, and radiotherapy on the primary focus.Conclusion.At present the patient is alive with no sign of initial disease. The forecast is favourable. Effectiveness of complex treatment of patients with sinonasal hemangiopericytoma was demonstrated. The primary role of endonasal surgery during treatment of sinonasal hemangiopericytoma in a 12-year-old patient was indicated.
- 19 July 2018
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 5 (2) , 120-126
Open AccessSinonasal Hemangiopericytoma in a 12-year-old Boy: Rare Clinical Case
Background.Hemangiopericytoma is a rare type of tumor of vascular origin and unknown malignant potential.Case Report.The article presents clinical case which is rarely observed, especially in children. A 12-year-old boy was admitted to Research Institute of Pediatric Oncology and Hematology with results of head MRI performed at a local clinic which demonstrated presence of a tumor of parameningeal localization. A patient passed complete clinical examination including some radiation diagnostic techniques, MRI, morphological, and immunohistochemical analyses and was diagnosed with sinonasal hemangiopericytoma of parameningeal localization T1bN0M0. The examination schedule, tactics, and treatment methods were selected individually for this patient since a commonly acknowledged treatment method had not been developed due to the lack of statistically relevant number of patient cases. Basing on the data on disease treatment records in Europe and Russia, patient received a complex treatment: three courses of neoadjuvant polychemotherapy, transnasal resection of tumor, and radiotherapy on the primary focus.Conclusion.At present the patient is alive with no sign of initial disease. The forecast is favourable. Effectiveness of complex treatment of patients with sinonasal hemangiopericytoma was demonstrated. The primary role of endonasal surgery during treatment of sinonasal hemangiopericytoma in a 12-year-old patient was indicated.
- Open Access
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (4) , 269-282
Endoscopic Endonasal Approach for the Tumor Removal in Children with Nasal Cavity and Paranasal Sinuses Cancer with Skull Base Metastases
Эндоскопический эндоназальный подход к удалению опухолей полости носа и околоносовых пазух с распространением на основание черепа у детей
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (4) , 269-282
Open AccessEndoscopic Endonasal Approach for the Tumor Removal in Children with Nasal Cavity and Paranasal Sinuses Cancer with Skull Base Metastases
Эндоскопический эндоназальный подход к удалению опухолей полости носа и околоносовых пазух с распространением на основание черепа у детей
- Open Access
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (3) , 204-213
ANESTHETIC MANAGEMENT OF ENDOSCOPIC ENDONASAL SURGERIES IN PEDIATRIC ONCOLOGY
АНЕСТЕЗИОЛОГИЧЕСКОЕ ОБЕСПЕЧЕНИЕ ЭНДОСКОПИЧЕСКИХ ЭНДОНАЗАЛЬНЫХ ОПЕРАЦИЙ В ДЕТСКОЙ ОНКОЛОГИИ
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (3) , 204-213
Open AccessANESTHETIC MANAGEMENT OF ENDOSCOPIC ENDONASAL SURGERIES IN PEDIATRIC ONCOLOGY
АНЕСТЕЗИОЛОГИЧЕСКОЕ ОБЕСПЕЧЕНИЕ ЭНДОСКОПИЧЕСКИХ ЭНДОНАЗАЛЬНЫХ ОПЕРАЦИЙ В ДЕТСКОЙ ОНКОЛОГИИ
- Open Access
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (3) , 214-225
CLINICAL SIGNIFICANCE OF TRANSNASAL ENDOSCOPIC SURGERY IN THE TREATMENT OF CHILDREN WITH LOCALIZED PARAMENINGEAL SARCOMAS
КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ МЕТОДА ТРАНСНАЗАЛЬНОЙ ЭНДОСКОПИЧЕСКОЙ ХИРУРГИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ ДЕТЕЙ C САРКОМАМИ ПАРАМЕНИНГЕАЛЬНОЙ ЛОКАЛИЗАЦИИ
- 1 January 2017
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 4 (3) , 214-225
Open AccessCLINICAL SIGNIFICANCE OF TRANSNASAL ENDOSCOPIC SURGERY IN THE TREATMENT OF CHILDREN WITH LOCALIZED PARAMENINGEAL SARCOMAS
КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ МЕТОДА ТРАНСНАЗАЛЬНОЙ ЭНДОСКОПИЧЕСКОЙ ХИРУРГИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ ДЕТЕЙ C САРКОМАМИ ПАРАМЕНИНГЕАЛЬНОЙ ЛОКАЛИЗАЦИИ